Sophia Stoecklein

LMU University Hospital
Country flagGermany

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (31)

Year:

2026

Year:

2026

Year:

2026

Background Subjective cognitive decline (SCD) is common in older adults and may precede mild cognitive impairment (MCI). Whether longitudinal changes in self- or study partner (SP)-reported SCD improve early identification of individuals at risk for clinical progression, particularly along the Alzheimer’s disease (AD) biological continuum, remains unclear. Methods We pooled data from two longitudinal observational cohorts (DELCODE and ADNI). Cognitively unimpaired (CU) participants were recruited through public advertisement or memory clinics and included if baseline amyloid status, ≥2 SCD assessments, and clinical follow-up were available. SCD was assessed using the Everyday Cognition questionnaire (self- and SP-report). Linear mixed-effects models examined longitudinal associations between SCD trajectories, baseline AD biomarkers, and progression to incident MCI. Multivariable Cox proportional hazards models tested whether one-year changes in SCD predicted subsequent progression. Findings Among 770 participants (median age 69·9years [IQR 66·0–74·6]; 52·6% women; median follow-up 5·0years [4·0-7·0]), amyloid-positive individuals and those who progressed to MCI showed steeper longitudinal increases in both SCD reports. In amyloid-positive participants, only increases in SP-reported SCD differentiated progressors from non-progressors. One-year increases in SP-reported SCD predicted a higher risk of subsequent MCI compared with unchanged scores (hazard ratio 3·24 [95%CI 1·73-6·07]), with effects confined to amyloid-positive participants. Interpretation Longitudinal increases in SP-reported cognitive difficulties, particularly over short intervals, are associated with near-term progression to MCI in amyloid-positive CU older adults. SP-based longitudinal monitoring may represent a low-burden approach to support earlier clinical surveillance in aging populations. Funding German Center for Neurodegenerative Diseases, US National Institutes of Health.

Year:

2026

Gliomas tend to arise in specific brain regions and may integrate into functional circuits, suggesting they could be regulated by brain activity. However, it remains unclear whether glioma growth is related to system-level brain networks. Analyzing neuroimaging data from three datasets including 1,310 patients with cerebral gliomas, we identified and replicated a functionally connected glioma network, which overlaps with the action-mode network (AMN), somatomotor network (SMN), and action-related subcortical regions. Resting-state functional connectivity (RSFC) of the AMN successfully predicted the location of glioma occurrence in two independent datasets with complex tumor distributions. Remarkably, no patient had a glioma entirely outside the AMN, and over 89% of patients exhibited gliomas with at least 50% overlap with the network. Moreover, the spatial overlap between glioma location and the AMN demonstrated significant prognostic value in survival analyses, with higher AMN-tumor overlap associated with poorer overall survival. Notably, the acetylcholine transporter, a key player in glioma pathogenesis that drives transcriptional reprogramming, showed an expression pattern overlapping with the AMN. Meta-analytic annotations further linked the glioma network to processes of action initiation, execution, and feedback. These findings indicate that gliomas preferentially arise in circuits involved in action and highlight the central role of the AMN in glioma pathophysiology and growth.

Year:

2026

Lymphomas confined to the spinal epidural space at initial diagnosis are rare and referred to as primary spinal epidural lymphoma (PSEL). This study presents clinical, histopathological, and molecular insights from 13 PSEL cases, including follicular lymphoma (PSEL-FL, N = 4), extranodal marginal zone lymphoma (PSEL-MZL, N = 3), diffuse large B-cell lymphoma (PSEL-DLBCL, N = 5), and Burkitt lymphoma (PSEL-BL, N = 1). Despite localized presentation at initial diagnosis, PSEL with aggressive histologies demonstrated remarkably unfavorable outcomes, contrasting the highly indolent clinical course observed in indolent PSEL, particularly PSEL-FL. Molecular analysis showed similarities to nodal counterparts and separation by entity. Comparison of PSEL-FL and classic FL revealed activated tumor microenvironment-associated pathways, potentially supporting extranodal lymphoma growth in this rarely affected spinal epidural site.

Year:

2025

Year:

2024

Background Diagnostic criteria for progressive supranuclear palsy (PSP) include midbrain atrophy in MRI and hypometabolism in [ 18 F]fluorodeoxyglucose (FDG)-positron emission tomography (PET) as supportive features. Due to limited data regarding their relative and sequential value, there is no recommendation for an algorithm to combine both modalities to increase diagnostic accuracy. This study evaluated the added value of sequential imaging using state-of-the-art methods to analyse the images regarding PSP features. Methods The retrospective study included 41 PSP patients, 21 with Richardson’s syndrome (PSP-RS), 20 with variant PSP phenotypes (vPSP) and 46 sex- and age-matched healthy controls. A pretrained support vector machine (SVM) for the classification of atrophy profiles from automatic MRI volumetry was used to analyse T1w-MRI (output: MRI-SVM-PSP score). Covariance pattern analysis was applied to compute the expression of a predefined PSP-related pattern in FDG-PET (output: PET-PSPRP expression score). Results The area under the receiver operating characteristic curve for the detection of PSP did not differ between MRI-SVM-PSP and PET-PSPRP expression score (p≥0.63): about 0.90, 0.95 and 0.85 for detection of all PSP, PSP-RS and vPSP. The MRI-SVM-PSP score achieved about 13% higher specificity and about 15% lower sensitivity than the PET-PSPRP expression score. Decision tree models selected the MRI-SVM-PSP score for the first branching and the PET-PSPRP expression score for a second split of the subgroup with normal MRI-SVM-PSP score, both in the whole sample and when restricted to PSP-RS or vPSP. Conclusions FDG-PET provides added value for PSP-suspected patients with normal/inconclusive T1w-MRI, regardless of PSP phenotype and the methods to analyse the images for PSP-typical features.

Year:

2024

First small sample studies indicate that disturbances of spinal morphology may impair craniospinal flow of cerebrospinal fluid and result in neurodegeneration. The aim of this study was to evaluate the association of cervical spinal canal width and scoliosis with grey matter, white matter, ventricular and white matter hyperintensity volumes of the brain in a large study sample. Four hundred participants underwent whole-body 3 T magnetic resonance imaging. Grey matter, white matter and ventricular volumes were quantified using a warp-based automated brain volumetric approach. Spinal canal diameters were measured manually at the cervical vertebrae 2/3 level. Scoliosis was evaluated using manual measurements of the Cobb angle. Linear binomial regression analyses of measures of brain volumes and spine anatomy were performed while adjusting for age, sex, hypertension, cholesterol levels, body mass index, smoking and alcohol consumption. Three hundred eighty-three participants were included [57% male; age: 56.3 (±9.2) years]. After adjustment, smaller spinal canal width at the cervical vertebrae 2/3 level was associated with lower grey matter (P = 0.034), lower white matter (P = 0.012) and higher ventricular (P = 0.006, inverse association) volume. Participants with scoliosis had lower grey matter (P = 0.005), lower white matter (P = 0.011) and larger brain ventricular (P = 0.003) volumes than participants without scoliosis. However, these associations were attenuated after adjustment. Spinal canal width at the cervical vertebrae 2/3 level and scoliosis were not associated with white matter hyperintensity volume before and after adjustment (P > 0.864). In our study, cohort smaller spinal canal width at the cervical vertebrae 2/3 level and scoliosis were associated with lower grey and white matter volumes and larger ventricle size. These characteristics of the spine might constitute independent risk factors for neurodegeneration.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Collaborators (33)

David Eidelberg

Professor

Donald & Barbara Zucker School of Medicine at Hofstra/Northwell

UNITED STATES
View details

Enrico Schulz

Principle Investigator

Ludwig-Maximilians-Universität München

GERMANY
View details

Daniel Keeser

RG Neuromodulation And Multimodal Neuroimaging, RG Clinical Deep Phenotyping (CDP)

Ludwig-Maximilians-Universität München

GERMANY
View details

Matthias Schmid

Full professor / Director

University of Bonn

GERMANY
View details

Andrea Schmitt

Klinikum der Universität München

GERMANY
View details

Zhuanghua Shi

Professor

Ludwig-Maximilians-Universität München

GERMANY
View details

Astrid Roeh

University Hospital Augsburg

GERMANY
View details

Florian Raabe

Group Leader & Deputy Chief Physician

Max Planck Institute of Psychiatry

GERMANY
View details

Anne Hilgendorff

Prof. (apl.) Dr. med.; Head Translation in Neonatology

Carl von Ossietzky Universität Oldenburg

GERMANY
View details

Joerg-Christian Tonn

-

GERMANY
View details

Ayda Rostamzadeh

University of Cologne

GERMANY
View details

Lukas Roell

University of Melbourne

AUSTRALIA
View details

Olaf Dietrich

Ruprecht Karls Universität Heidelberg

GERMANY
View details

Matthias Brendel

-

GERMANY
View details

Bernd Wolfarth

Charité - Universitätsmedizin Berlin

GERMANY
View details

Alida Kindt-Dunjko

Leiden University

NETHERLANDS
View details

Susanne Rospleszcz

University Medical Center Freiburg

GERMANY
View details

Philipp Karschnia

Friedrich-Alexander Universität Erlangen-Nürnberg

GERMANY
View details

Adrien Holzgreve

LMU University Hospital

GERMANY
View details

Josef Priller

-

UNITED KINGDOM
View details

Matthis Synofzik

Professor

Hertie Institute for clinical brain research

GERMANY
View details

Isabel Maurus

University Hospital

GERMANY
View details

Ralph Buchert

University Medical Center Hamburg-Eppendorf

GERMANY
View details

Robert Perneczky

Professor

Ludwig-Maximilians-Universität München

GERMANY
View details

Jochen Herms

Full professor

Ludwig-Maximilians-Universität München

GERMANY
View details

Johannes Levin

Professor for Clinical Neurodegeneration

Ludwig-Maximilians-Universität München

GERMANY
View details

Emrah Düzel

Deutsches Zentrum für Neurodegenerative Erkrankungen

GERMANY
View details

Hesheng Liu

Professor

Medical University of South Carolina

UNITED STATES
View details

Claudia Bartels

University Medical Center Göttingen

GERMANY
View details

Andreas W. Flemmer

Department Head

Ludwig-Maximilians-Universität München

GERMANY
View details

Stefan Teipel

Rostock University Medical Center

GERMANY
View details

Peter Falkai

Chair

Ludwig-Maximilians-Universität München

GERMANY
View details

Lars Paeger

Principal Investigator, Head of In vivo Electrophysiology Laboratory

Deutsches Zentrum für Neurodegenerative Erkrankungen

GERMANY
View details